Literature DB >> 17224022

In vitro assessment of motility and proliferation of human osteogenic cells on different isolated extracellular matrix components compared with enamel matrix derivative by continuous single-cell observation.

Marcus Oliver Klein1, Christoph Reichert, Dorothee Koch, Sigrid Horn, Bilal Al-Nawas.   

Abstract

OBJECTIVES: The composition of the extracellular matrix (ECM) plays a substantial role in bone remodelling, fracture healing and osseointegration of dental implants by regulating proliferation, migration and finally differentiation of osteogenic cell populations. Emdogain, a composition of an enamel matrix derivative (EMD), has been introduced as a potential candidate to promote tissue regeneration. We investigated whether EMD could serve as a potential promoter of cell proliferation and motility as a dynamic cell response and compared the results with the ubiquitous single ECM components type I collagen and laminin.
MATERIAL AND METHODS: In the investigation presented, we used a continuous observation method for the analysis of migratory and proliferative patterns of individual cells. We analyzed the response of four osteoblastic cell lines to specific extracellular ligands (type I collagen, laminin and EMD) over a period of 24 h compared with untreated glass surface and bovine serum albumin (BSA) as control groups.
RESULTS: Type I collagen and laminin promoted cell motility significantly compared with the control groups and, in part, compared with EMD as well. The analysis of all 451 investigated cells revealed the following mean values for cell motiliy: untreated glass (n=99): 5.46+/-2.74 microm/h, BSA (n=89): 6.35+/-2.43 microm/h, type I collagen (n=108): 8.77+/-3.42 microm/h, laminin (n=74): 9.89+/-5.10 microm/h and EMD (n=81): 7.92+/-3.35 microm/h. Proliferation rates on the different surfaces were heterogenous for all investigated cell lines and varied from 0% to 50% within 24 h without a correlation to cell motility.
CONCLUSION: In our study, EMD promotes cell motility better than the control groups. The two investigated single ECM components type I collagen and laminin promoted cell motility superior to EMD. This supports the hypothesis that EMD promotes a less mobile but more differentiated osteogenic phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17224022     DOI: 10.1111/j.1600-0501.2006.01279.x

Source DB:  PubMed          Journal:  Clin Oral Implants Res        ISSN: 0905-7161            Impact factor:   5.977


  5 in total

1.  Combinatorial growth of oxide nanoscaffolds and its influence in osteoblast cell adhesion.

Authors:  Claudia Y Acevedo-Morantes; Roberto A Irizarry-Ortiz; Pablo G Caceres-Valencia; Surinder P Singh; Jaime E Ramirez-Vick
Journal:  J Appl Phys       Date:  2012-05-17       Impact factor: 2.546

2.  Implementation of new software for fast screening of cell compatibility on surface modifications using low-contrast time-lapsed microscopy.

Authors:  Dan Dominik Brüllmann; Marc O Klein; Bilal Al-Nawas; Sigrid Horn; Verena Büsser; Barbara Jung; Wilfried Wagner; Bernd d'Hoedt
Journal:  Clin Oral Investig       Date:  2009-08-21       Impact factor: 3.573

3.  Evaluation of Enamel Matrix Derivative (EMD) Teratogenicity on the Rat Embryo Neural Crest Culture.

Authors:  Maliheh Mamashli; Mina Ramezani; Maliheh Parsa; Seyyed Nasser Ostad
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

4.  Rho kinase inhibitors stimulate the migration of human cultured osteoblastic cells by regulating actomyosin activity.

Authors:  Xuejiao Zhang; Cheng Li; Huiling Gao; Hiroaki Nabeka; Tetsuya Shimokawa; Hiroyuki Wakisaka; Seiji Matsuda; Naoto Kobayashi
Journal:  Cell Mol Biol Lett       Date:  2011-03-09       Impact factor: 5.787

5.  In vitro proliferation of human osteogenic cells in presence of different commercial bone substitute materials combined with enamel matrix derivatives.

Authors:  Christoph Reichert; Bilal Al-Nawas; Ralf Smeets; Adrian Kasaj; Werner Götz; Marcus O Klein
Journal:  Head Face Med       Date:  2009-11-12       Impact factor: 2.151

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.